Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Mirati Therapeutics Inc    MRTX

MIRATI THERAPEUTICS INC (MRTX)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 04:00:00 pm
64.92 USD   +1.22%
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
63.71(c) 64.8(c) 62.47(c) 64.14(c) 64.92(c) Last
1 197 809 982 852 830 070 1 927 653 510 185 Volume
+4.68% +1.71% -3.60% +2.67% +1.22% Change
More quotes
Financials (USD)
Sales 2018 10,5 M
EBIT 2018 -102 M
Net income 2018 -97,9 M
Finance 2018 205 M
Yield 2018 -
Sales 2019 1,39 M
EBIT 2019 -136 M
Net income 2019 -133 M
Finance 2019 440 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 182x
EV / Sales2019 1 203x
Capitalization 2 111 M
More Financials
Company
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are... 
More about the company
Surperformance© ratings of Mirati Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MIRATI THERAPEUTICS INC
01/17MIRATI THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (for..
AQ
01/16MIRATI THERAPEUTICS, INC. : Results of Operations and Financial Condition (form ..
AQ
2018MIRATI THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2018MIRATI THERAPEUTICS : New partner announced as part of lung cancer research
AQ
2018MIRATI : 3Q Earnings Snapshot
AQ
2018MIRATI THERAPEUTICS, INC. : Results of Operations and Financial Condition, Finan..
AQ
2018MIRATI THERAPEUTICS : Shares Fall On New Data For Lung Cancer Drug Combo
AQ
2018Mirati falls on updated response data for sitravatinib in NSCLC
AQ
2018MIRATI THERAPEUTICS : Announces Presentation Of KRAS G12C Chemistry Advances At ..
PU
2018MIRATI THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financia..
AQ
More news
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart MIRATI THERAPEUTICS INC
Duration : Period :
Mirati Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRATI THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 65,2 $
Spread / Average Target 0,47%
EPS Revisions
Managers
NameTitle
Charles M. Baum President, Chief Executive Officer & Director
Rodney W. Lappe Executive Chairman
Jamie A. Donadio Chief Financial Officer & Senior Vice President
Isan Chen EVP, Chief Medical & Development Officer
James G. Christensen Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
MIRATI THERAPEUTICS INC53.04%2 111
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS14.97%49 757
REGENERON PHARMACEUTICALS11.75%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300